Curtis Cooper

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. ncbi Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy
    Curtis Cooper
    The Ottawa Hospital General Campus, Module G12, Ottawa, ON 1H 8L6, Canada
    Expert Rev Vaccines 10:417-27. 2011
  2. ncbi Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting
    Curtis Cooper
    Department of Medicine, Division of Infectious Diseases, University of Ottawa, Canada
    Clin Infect Dis 55:418-25. 2012
  3. ncbi High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults
    Curtis Cooper
    The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, Canada
    HIV Clin Trials 13:23-32. 2012
  4. ncbi African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology
    Edward Mills
    Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West Hamilton, L8N 3Z5, Canada
    Nutr J 4:19. 2005
  5. ncbi Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    J Int AIDS Soc 14:52. 2011
  6. ncbi Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
    Curtis L Cooper
    Coley Pharmaceutical Canada, Ottawa, Canada
    J Immune Based Ther Vaccines 6:3. 2008
  7. ncbi CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection
    Jonathan B Angel
    Ottawa Health Research Institute, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada
    J Immune Based Ther Vaccines 6:4. 2008
  8. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  9. ncbi Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis
    Edward J Mills
    Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
    Ann Clin Microbiol Antimicrob 8:23. 2009
  10. ncbi Evaluation of VCH-759 monotherapy in hepatitis C infection
    Curtis Cooper
    The Ottawa Hospital, Division of Infectious Disease, Ottawa, ON, Canada K1H 8L6
    J Hepatol 51:39-46. 2009

Collaborators

Detail Information

Publications81

  1. ncbi Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy
    Curtis Cooper
    The Ottawa Hospital General Campus, Module G12, Ottawa, ON 1H 8L6, Canada
    Expert Rev Vaccines 10:417-27. 2011
    ..1018 ISS plus recombinant hepatitis B surface antigen has been demonstrated to achieve these goals in immune competent and vaccine-hyporesponsive populations without compromising recipient safety...
  2. ncbi Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting
    Curtis Cooper
    Department of Medicine, Division of Infectious Diseases, University of Ottawa, Canada
    Clin Infect Dis 55:418-25. 2012
    ..Expertise in HCV antiviral resistance, drug metabolism, and drug-drug interactions and optimization of drug adherence are now key requirements in the DAA era...
  3. ncbi High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults
    Curtis Cooper
    The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, Canada
    HIV Clin Trials 13:23-32. 2012
    ..More severe influenza disease and poor vaccine immunogenicity in HIV-infected patients necessitate improved immunization strategies to maximize vaccine efficacy...
  4. ncbi African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology
    Edward Mills
    Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West Hamilton, L8N 3Z5, Canada
    Nutr J 4:19. 2005
    ..Efforts should also be directed at evaluating the possible benefits of natural products in HIV/AIDS treatment...
  5. ncbi Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    J Int AIDS Soc 14:52. 2011
    ....
  6. ncbi Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
    Curtis L Cooper
    Coley Pharmaceutical Canada, Ottawa, Canada
    J Immune Based Ther Vaccines 6:3. 2008
    ..A potent immune activator such as TLR9 agonist CpG oligodeoxynucleotide (CpG) may complement current treatment approaches...
  7. ncbi CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection
    Jonathan B Angel
    Ottawa Health Research Institute, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada
    J Immune Based Ther Vaccines 6:4. 2008
    ....
  8. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  9. ncbi Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis
    Edward J Mills
    Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
    Ann Clin Microbiol Antimicrob 8:23. 2009
    ..Treatment guidelines vary on optimal treatment strategies. We aimed to determine the effects of different antifungal therapies on global response rates, mortality and safety...
  10. ncbi Evaluation of VCH-759 monotherapy in hepatitis C infection
    Curtis Cooper
    The Ottawa Hospital, Division of Infectious Disease, Ottawa, ON, Canada K1H 8L6
    J Hepatol 51:39-46. 2009
    ..VCH-759 is a non-nucleoside inhibitor of HCV RNA-dependent polymerase with sub-micromolar IC(50) values versus genotype 1a/1b replicons...
  11. ncbi Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo
    Curtis L Cooper
    Division of Infectious Diseases, The Ottawa Hospital General Campus, Ottawa, ON, Canada
    Front Biosci 9:338-41. 2004
    ..05). These data confirm in vitro that apoptosis susceptibility is altered by ART, including in HIV-negative patients who take PEP...
  12. ncbi Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection
    Curtis L Cooper
    Division of Infectious Diseases, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
    AIDS 21:71-6. 2007
    ..Hyperlipidemia is a recognized complication of HIV antiretroviral therapy. The interactions between HIV, hepatitis C virus (HCV), antiretroviral agents and lipids are not well understood...
  13. ncbi Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia
    Curtis L Cooper
    University of Ottawa Hospital, Division of Infectious Diseases, The Ottawa Hospital General Campus, The Ottawa Health Research Institute, Ontario, Canada
    HIV Clin Trials 7:251-4. 2006
    ..Infectious complications were assessed in 25 HIV-HCV coinfected patients receiving 29 courses of HCV therapy (786 person-weeks)...
  14. ncbi Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review
    C L Cooper
    University of Ottawa, Ottawa Hospital Division of Infectious Diseases, and Health Research Institute, Ottawa, Ontario, Canada
    HIV Med 8:1-7. 2007
    ..This dosing strategy is currently under evaluation...
  15. ncbi Barriers preventing liver transplantation in Canadians with HIV-infection--perceptions of HIV specialists
    Curtis L Cooper
    University of Ottawa, Ottawa, Canada
    Can J Gastroenterol 21:179-82. 2007
    ..Based on these data, it is believed that these issues should be the focus of efforts designed to increase access to transplantation in Canadians with end-stage liver disease and concurrent HIV...
  16. ncbi Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection
    Curtis L Cooper
    Department of Medicine, Division of Infectious Diseases, The Ottawa Hospital, University of Ottawa, G12 501 Smyth Road, Ottawa, Ontario, Canada
    Int J STD AIDS 18:546-50. 2007
    ..Attention to this and strategies targeting substance abuse and adherence in HIV-HCV are predicted to increase the duration of HAART...
  17. ncbi An overview of HIV and chronic viral hepatitis co-infection
    Curtis L Cooper
    University of Ottawa Hospital, Division of Infectious Diseases The Ottawa Hospital, The Ottawa Hospital General Campus, Room G12, 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6
    Dig Dis Sci 53:899-904. 2008
    ..Given the high prevalence of HBV and HCV co-infection, chronic viral hepatitis will influence the health and treatment of HIV-infected individuals for the foreseeable future...
  18. ncbi A review of low-dose ritonavir in protease inhibitor combination therapy
    C L Cooper
    Division of Infectious Diseases, The Ottawa Hospital General Campus, Ottawa, ON, Canada K1H 8L6
    Clin Infect Dis 36:1585-92. 2003
    ..Additional study will elucidate the advantages and disadvantages of twice-daily, low-dose ritonavir-boosted regimens and determine whether once-daily regimens based on this principle will have a lasting role in clinical practice...
  19. ncbi Influenza vaccine oculorespiratory syndrome incidence is reduced in HIV
    Curtis Cooper
    University of Ottawa, The Ottawa Hospital Division of Infectious Diseases, Ottawa, Ontario, Canada
    Vaccine 29:7876-7. 2011
    ..We assessed ORS incidence in a randomized influenza vaccine trial of HIV participants. The overall incidence was 0.8% suggesting that influenza vaccine ORS incidence is reduced in HIV...
  20. ncbi CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years
    C L Cooper
    Division of Infectious Diseases, University of Ottawa at Ottawa Hospital, Ottawa Health Research Institute, Ottawa, Canada
    Clin Infect Dis 46:1310-4. 2008
    ..We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and longevity of the seroprotective response over 48 weeks. We now report data for the 5-year period following vaccination...
  21. ncbi Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success
    Curtis Cooper
    Division of Infectious Diseases, Department of Medicine, The Ottawa Hospital, G12 501 Smyth Road, Ottawa, Ontario K1H 8L6
    Can J Gastroenterol 24:385-90. 2010
    ....
  22. ncbi Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection
    Curtis L Cooper
    Division of Infectious Diseases, Ottawa Hospital, University of Ottawa, Ottawa, Ontario K1H 8L6, Canada
    Clin Infect Dis 35:873-9. 2002
    ..A prospective clinical trial of sufficient size and duration may help clarify this issue. This may be clinically relevant, because lower HCV RNA levels are a predictive factor for favorable response to HCV antiviral therapy...
  23. ncbi Obstacles to successful HCV treatment in substance addicted patients
    Curtis L Cooper
    University of Ottawa Hospital, Division of Infectious Diseases, The Ottawa Hospital, Ottawa, Canada
    J Addict Dis 27:61-8. 2008
    ..These interventions include substance cessation programs, safe injection settings to reduce HCV incidence and multidisciplinary teams to facilitate HCV treatment provision...
  24. ncbi Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians
    Curtis L Cooper
    University of Ottawa, Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ontario
    Can J Gastroenterol 22:677-80. 2008
    ..It is unclear what proportion of HCV-infected Aboriginal people receive therapy relative to other populations...
  25. ncbi The influence of race and language on chronic hepatitis C virus infection management
    Celine Giordano
    University of Ottawa, The Ottawa Hospital, Division of Infectious Diseases, Ottawa, Canada
    Eur J Gastroenterol Hepatol 21:131-6. 2009
    ..g. translated written documents; use of reliable, trained translators in the clinic setting) will facilitate the delivery of an equivalent level of care to all patients living with HCV...
  26. ncbi Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus
    Curtis L Cooper
    Division of Infectious Diseases, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada, K1H 8L6
    Clin Infect Dis 34:1259-63. 2002
    ..Dual-PI therapy and inclusion of ritonavir do not seem to increase the rates of hepatotoxicity in PI-treated, HIV-HCV coinfected subjects...
  27. ncbi Evaluation of nevirapine-switch strategies for HIV treatment
    C L Cooper
    Division of Infectious Diseases, University of Ottawa Hospital, The Ottawa Hospital General Campus, 501 Smyth Road, Ottawa, Ontario, Canada
    HIV Med 7:537-43. 2006
    ..There is no immunological cost. There is probably an overall benefit in terms of the metabolic milieu...
  28. ncbi Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults
    Curtis Cooper
    University of Ottawa Division of Infectious Diseases, Ottawa, Canada
    PLoS ONE 6:e17758. 2011
    ..The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to improve vaccine efficacy...
  29. ncbi Therapeutic interventions for HIV infection and chronic viral hepatitis
    Curtis L Cooper
    Division of Infectious Diseases, The Ottawa Hospital General Campus, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Clin Infect Dis 41:S69-72. 2005
    ..Safe and virologically active treatment of coinfection with HIV and hepatitis B virus can be concurrently achieved by the use of combination antiretroviral therapy regimens containing lamivudine and/or tenofovir...
  30. ncbi Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV
    Curtis L Cooper
    Division of Infectious Diseases, University of Ottawa, The Ottawa Hospital, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    Clin Infect Dis 41:S105-9. 2005
    ..The interactions between human immunodeficiency virus (HIV), hepatitis C virus (HCV), alcohol, and antiretroviral therapy are complex...
  31. ncbi CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults
    Curtis L Cooper
    Division of Infectious Diseases, University of Ottawa at The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada
    AIDS 19:1473-9. 2005
    ..HIV patients are vaccine hyporesponsive...
  32. ncbi Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection
    C L Cooper
    University of Ottawa, Ottawa, Canada
    Can J Gastroenterol 20:31-5. 2006
    ..The clinical relevance of accurate HCV measurement in HIV-HCV coinfection is discussed...
  33. ncbi Therapies for HIV and viral hepatitis coinfection
    Curtis L Cooper
    The Ottawa Hospital General Campus, Room G12, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada
    Expert Rev Anti Infect Ther 3:81-9. 2005
    ..HepatitisC virus antiviral therapy should, in most cases, be reserved for those achieving HIV RNA suppression and immune restoration from highly active antiretroviral therapy or with nadir CD4 T-lymphocytes above 350 cells/microl...
  34. ncbi CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study
    C L Cooper
    Division of Infectious Diseases, University of Ottawa at The Ottawa Hospital and Ottawa Health Research Institute, Ottawa, Canada
    J Clin Immunol 24:693-701. 2004
    ..In summary, CPG 7909 as an adjuvant to Engerix-B was well-tolerated and enhanced vaccine immunogenicity. CPG 7909 may allow the development of a two-dose prophylactic HBV vaccine...
  35. ncbi Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa
    Curtis L Cooper
    University of Ottawa Division of Infectious Diseases, Room G12, The Ottawa Hospital General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Int J Infect Dis 13:302-6. 2009
    ..Failure to act now may diminish the milestones and the gains made with antiretroviral therapy in the developing world...
  36. ncbi Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity
    Curtis L Cooper
    University of Ottawa, Division of Infections Diseases, The Ottawa Hospital General Campus, Ontario, Canada
    Curr Opin Infect Dis 25:26-35. 2012
    ..As an at-risk population for more severe influenza illness, particular concern regarding HIV patients triggered a focused effort to evaluate disease burden and vaccine efficacy in these populations...
  37. ncbi Natural history of HIV and HCV coinfection
    Curtis L Cooper
    Division of Infectious Diseases, University of Ottawa, Ottawa Hospital, Room G12 501 Smyth Road, Ottawa, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 2:147-51. 2003
    ..Given these interactions and the high prevalence of HIV/HCV coinfection, chronic HCV infection will greatly affect the morbidity, mortality, and medical management of HIV patients, and HIV will also affect the care of patients with HCV...
  38. ncbi Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults
    Curtis Cooper
    The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, Canada
    HIV Clin Trials 12:275-6. 2011
    ..Neither seroconversion nor seroprotection were predicted by vitamin D use for any of the 3 vaccine strains. There is no evidence of improved influenza vaccine immunogenicity with vitamin D supplementation in this HIV-positive population...
  39. ncbi Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia
    Curtis L Cooper
    Division of Infectious Diseases, Health Research Institute, The Ottawa Hospital, University of Ottawa, ON, Canada
    Clin Infect Dis 42:1674-8. 2006
    ..Reduction in interferon dose and/or dosing with granulocyte colony-stimulating factor in those with neutropenia is not supported by this analysis...
  40. ncbi Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection
    C L Cooper
    Division of Infectious Diseases, The Ottawa Hospital, University of Ottawa, Ottawa, Canada
    HIV Med 7:32-7. 2006
    ..Despite the benefits of HAART, initiation of antiretroviral therapy in HIV-HCV co-infected patients is often delayed as a consequence of patient and physician concern pertaining to liver toxicity. It is unclear whether this is justified...
  41. ncbi Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy
    Darrell H S Tan
    Department of Medicine, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 58:38-46. 2011
    ..Controversy about the relative performance of abacavir (ABC)/lamivudine (3TC) and tenofovir (TDF)/emtricitabine (FTC) in initial combination antiretroviral therapy (cART) exists...
  42. ncbi Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection
    Julia Thorpe
    Department of Medicine, Divisions of Infectious Diseases Immunodeficiency, Royal Victoria Hospital, Canada
    AIDS 25:967-75. 2011
    ..We examined the impact of ART interruption on liver fibrosis progression in co-infected adults, using the aspartate aminotransferase-to-platelet ratio index (APRI) as a surrogate marker of liver fibrosis...
  43. ncbi CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy
    Marina B Klein
    Department of Medicine, Divisions of Infectious Diseases Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Contemp Clin Trials 29:617-30. 2008
    ..Effective prevention of a broad range of neuropsychiatric symptoms by citalopram has the potential to diminish PEG-IFN-alpha associated morbidity and consequently, allow a greater number of patients to complete full therapy...
  44. ncbi Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C
    Louise Balfour
    The Ottawa Hospital Division of Infectious Diseases Viral Hepatitis Program, University of Ottawa, Ontario
    Can J Gastroenterol 20:81-6. 2006
    ....
  45. ncbi Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients
    Mark W Hull
    British Columbia Centre for Excellence in HIV AIDS, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    AIDS 26:1789-94. 2012
    ..We evaluated factors associated with insulin resistance in a cohort of HIV/HCV-coinfected patients and determined the effect of insulin resistance on the development of hepatic fibrosis...
  46. ncbi Once daily dosing improves adherence to antiretroviral therapy
    Janet Raboud
    Division of Infectious Disease, University Health Network, Toronto, ON, Canada
    AIDS Behav 15:1397-409. 2011
    ..Other independent correlates of suboptimal adherence were younger age, lower positive social interaction and increased frequency of consuming > 6 alcoholic drinks on one occasion...
  47. ncbi Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy
    Martin Potter
    Department of Medicine, Division of Infectious Diseases, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    AIDS 24:1857-65. 2010
    ..We examined the impact of spontaneous clearance of HCV on CD4(+) T-lymphocyte count progression before and after initiation of antiretroviral therapy (ART) in HIV-HCV coinfected adults...
  48. ncbi Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    PLoS Med 3:e438. 2006
    ..We systematically reviewed the literature to determine patient-reported barriers and facilitators to adhering to antiretroviral therapy...
  49. ncbi The management of chronic viral hepatitis: a Canadian consensus conference 2004
    Morris Sherman
    University of Toronto, Toronto, Ontario, Canada
    Can J Gastroenterol 18:715-28. 2004
    ..The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care...
  50. ncbi Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort
    Curtis Cooper
    The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Canada
    AIDS 25:777-86. 2011
    ..We aimed to evaluate the effectiveness of liver transplantation in HIV-hepatitis co-infected patients using a meta-analysis and individual patient data meta-analysis as a synthetic cohort...
  51. ncbi Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes
    Celine Giordano
    Division of Infection Diseases The University of Ottawa, Ottawa, Ontario, Canada
    Eur J Gastroenterol Hepatol 21:963-8. 2009
    ..Disparities in care related to immigration status as well as to race and language are well recognized. Identifying and understanding these disparities is vital to the provision of optimal and inclusive HCV care...
  52. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
    ..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
  53. ncbi HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia
    C Diong
    University Health Network, Toronto, Ontario, Canada
    HIV Med 12:403-11. 2011
    ..Hyperlipidaemia is a recognized complication of HIV antiretroviral therapy. The interactions among HIV, viral hepatitis, antiretroviral therapies and lipids are poorly understood...
  54. ncbi HIV knowledge among Canadian-born and sub-Saharan African-born patients living with HIV
    Heather E Tulloch
    University of Ottawa Heart Institute, Prevention and Rehabilitation Centre, 40 Ruskin St, Ottawa, ON, K1Y 4W7, Canada
    J Immigr Minor Health 14:132-9. 2012
    ....
  55. ncbi Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy
    Janet Raboud
    University Health Network, Toronto, Ontario, Canada
    HIV Clin Trials 11:340-50. 2010
    ..To determine the effects of gender and calendar year on time to and duration of virologic suppression among HIV-infected antiretroviral-naïve individuals initiating combination antiretroviral therapy (cART)...
  56. ncbi Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Canada
    AIDS 25:851-5. 2011
    ..Funders have been reticent to recommend earlier initiation of treatment. We aimed to examine the effect of baseline CD4 cell count on mortality using data from HIV patients receiving combination antiretroviral therapy (cART) in Uganda...
  57. ncbi Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study
    Janet Raboud
    Toronto General Research Institute, University Health Network, Room 13EN226, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada
    BMC Med Res Methodol 13:31. 2013
    ..These dissimilarities may limit the generalizability of results of research studies. Quantification of the participation bias is essential for the interpretation of research findings...
  58. ncbi Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis
    Tahir Shaikh
    Department of Medicine, University of Ottawa, Ottawa, Canada
    Can J Gastroenterol 26:148-50. 2012
    ..background⁄..
  59. ncbi A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study
    Curtis Cooper
    The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    HIV Clin Trials 13:179-88. 2012
    ..A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal...
  60. ncbi A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults
    Curtis Cooper
    University of Ottawa, Division of Infectious Diseases The Ottawa Hospital, Ottawa Health Research Institute Methods Centre, Ottawa, Ontario
    Can J Infect Dis Med Microbiol 19:419-23. 2008
    ..HIV-seropositive adults are at an increased risk for influenza infection. They also develop more severe influenza disease and are hyporesponsive to current influenza vaccinations...
  61. ncbi Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic
    Louise Balfour
    Viral Hepatitis Unit, Division of Infectious Diseases, The Ottawa Hospital, Ottawa, Ontario
    Can J Public Health 95:272-7. 2004
    ..To define self-reported hepatitis C knowledge, health care needs, and patient satisfaction in a representative cohort of hepatitis C virus (HCV)-infected adults treated at a university hospital-based viral hepatitis clinic in Canada...
  62. ncbi A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression
    Mona R Loutfy
    University of Toronto, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 55:451-9. 2010
    ..To determine the long-term impact of immunologic discordance (viral load <50 copies/mL and CD4+ count <=200 cells/mm3) in antiretroviral-naive patients initiating combination antiretroviral therapy (cART)...
  63. ncbi Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
    Mazin Barry
    University of Ottawa, The Ottawa Hospital, Division of Infectious Diseases, Room G12 501 Smyth Road, Ottawa, K1H 8L6, ON, Canada
    Expert Opin Biol Ther 7:1731-7. 2007
    ..Although additional supporting data are required, this represents a promising strategy to facilitate worldwide HBV prevention efforts...
  64. ncbi Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
    C L Cooper
    Coley Pharmaceutical, Ottawa, ON, Canada
    Vaccine 22:3136-43. 2004
    ..048) and B/Harbin/7/94 (P = 0.0057), restoring these to the level seen with full-dose vaccine. These results suggest that addition of CPG 7909 to Fluarix may allow the use of reduced vaccine doses without reduced immunogenicity...
  65. ncbi Fasciitis complicating subcutaneous injection of interferon beta
    C L Cooper
    Viral Hepatitis Investigative Unit, Department of Medicine, University of Manitoba, Winnipeg, Canada
    Can J Gastroenterol 14:81B-82B. 2000
    ..This case is a dramatic example of why sterile technique during infections must be adhered to...
  66. ncbi Development and psychometric validation of the HIV Treatment Knowledge Scale
    L Balfour
    Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario, Canada
    AIDS Care 19:1141-8. 2007
    ..It has important applications as a clinical teaching tool with patients and healthcare workers and it could be used as an outcome indicator in HIV educational intervention studies...
  67. ncbi Fluarix, inactivated split-virus influenza vaccine
    G W Rose
    Division of Infectious Diseases, The Ottawa Hospital, University of Ottawa, Ottawa, ON, K1H 8L6, Canada
    Expert Opin Biol Ther 6:301-10. 2006
    ..Other directions to explore in an effort to secure future vaccine supply are considered...
  68. ncbi A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART
    L Balfour
    Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario, USA
    AIDS Care 18:830-8. 2006
    ..9; p < 0.05). The STAART intervention enhanced HIV treatment readiness by better preparing patients prior to initiating HAART. It was also beneficial for reducing depressive symptoms in depressed, HIV-positive patients...
  69. ncbi Randomized trials stopped early for harm in HIV/AIDS: a systematic survey
    Edward Mills
    Centre for International Health and Human Rights Studies, North York, Ontario, Canada
    HIV Clin Trials 7:24-33. 2006
    ..We assessed the prevalence of randomized clinical trials (RCTs) stopped early for harm in HIV/AIDS and determined the quality of reporting of methods to inform the decision to stop the trial...
  70. ncbi A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases
    Kaveri Gupta
    Division of Infectious Diseases, University of Ottawa, Ottawa, Ontario, Canada
    Drugs R D 9:137-45. 2008
    ..05) at all time points from month 24 to month 60. There is great potential for CpG ODN as vaccine adjuvants and as therapeutic immune modulators. The use of these molecules as a hepatitis B vaccine adjuvant is most promising...
  71. ncbi Long-Term Health Care Interruptions Among HIV-Positive Patients in Uganda
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada Stanford Prevention Research Center, School of Medicine, Stanford University, Stanford, CA Mildmay Uganda, Kampala, Uganda Division of Infectious Diseases, The Ottawa Hospital, Ottawa, Ontario, Canada Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa and Médecins Sans Frontières, Geneva, Switzerland
    J Acquir Immune Defic Syndr 63:e23-7. 2013
    ..We examined risk factors for health care interruptions and loss to follow-up within a cohort receiving ART in Uganda...
  72. ncbi Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection
    Curtis L Cooper
    Division of Infectious Diseases, University of Ottawa at The Ottawa Hospital, and the Ottawa Health Research Institute, Ottawa, ON, Canada
    AIDS 18:337-8. 2004
    ..Our observations challenge conventional wisdom that HCV polymerase chain reaction-negative patients with normal liver enzymes are 'cured'...
  73. ncbi Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death
    Cecilia T Costiniuk
    Department of Internal Medicine, University of Ottawa, Canada
    Clin Infect Dis 47:198-202. 2008
    ..Clinical data in other patient populations demonstrate increased rates of cardiovascular events, thrombosis, malignancy, and death among ESA recipients. Event rates in the context of HCV treatment are unknown...
  74. ncbi Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response
    Claire Anne Siegrist
    Department of Pediatrics, Center for Vaccinology and Neonatal Immunology, University of Geneva, C M U, 1 rue Michel Servet, 1211 Geneva 4, Switzerland
    Vaccine 23:615-22. 2004
    ..This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity...
  75. ncbi Development and validation of the HIV Medication Readiness Scale
    Louise Balfour
    Ottawa Hospital General Campus, Ottawa, Ontario, Canada
    Assessment 14:408-16. 2007
    ..The HMRS is a brief, easy-to-use, clinically relevant tool that can assist in identifying people living with HIV at high risk of nonadherence, who might benefit from tailored readiness counseling prior to initiating HIV medications...
  76. ncbi Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus
    Cecilia T Costiniuk
    Department of Internal Medicine, University of Ottawa, Ottawa, Canada
    Can J Gastroenterol 22:376-80. 2008
    ..Oral cannabinoid-containing medications (OCs) ameliorate chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome. The efficacy of OCs in managing HCV treatment-related side effects is unknown...
  77. ncbi De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity
    Curtis L Cooper
    J Infect Dis 196:656-8. 2007
  78. ncbi Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed
    Stephen Kravcik
    Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    AIDS 21:1711-5. 2007
    ..To determine the safety of discontinuing Pneumocystis jiroveci pneumonia (PCP) prophylaxis, in patients on effective antiretroviral therapy with CD4+ T-cell counts that have plateaued at < 200 cells/microl...
  79. ncbi Inflammation and repair in viral hepatitis C
    Manuela G Neuman
    In Vitro Drug Safety and Biotechnology, Department of Pharmacology, Biophysics and Global Health, Institute of Drug Research, University of Toronto, Toronto, ON, Canada
    Dig Dis Sci 53:1468-87. 2008
    ..This review will also aim to describe the importance of IFN-alpha-based therapies in HCV infection, ways of monitoring them, and associated complications...
  80. ncbi Influenza vaccination with 1/10th the full dose
    Curtis L Cooper
    N Engl J Med 351:2339-40. 2004
  81. ncbi Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity
    Rolf P G van Heeswijk
    Ottawa Hospital and Ottawa Health Research Institute, The University of Ottawa, Ontario, Canada
    Pharmacotherapy 25:1725-8. 2005
    ..To investigate the effect of high-dose vitamin C on cytochrome P450 (CYP) 3A4 activity, and to evaluate possible sex-specific effects on CYP3A4 activity...